{"id":24046,"date":"2023-12-20T21:30:00","date_gmt":"2023-12-20T21:30:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4298774_CN98774_0"},"modified":"2023-12-20T21:30:00","modified_gmt":"2023-12-20T21:30:00","slug":"ys-biopharma-responds-to-unauthorized-press-release-regarding-extraordinary-general-meeting","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=24046","title":{"rendered":"YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting"},"content":{"rendered":"<br \/>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">GAITHERSBURG, Md.<\/span>, Dec. 21, 2023 \/PRNewswire\/ &#8212; YS Biopharma Co., Ltd. (NASDAQ: YS) (&quot;YS Biopharma&quot; or the &quot;Company&quot;), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today issues an official response to the unauthorized press release disseminated <span id=\"spanHghltba68\">under our name.<\/span> We take this matter with utmost seriousness and wish to clarify the following points:<\/span><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<ol type=\"1\">\n<li><b>Mr. <span class=\"xn-person\">Yi Zhang&#8217;s<\/span> Chairmanship<\/b>: Our filing on Form 6-K with the U.S. Securities and Exchange Commission on <span class=\"xn-chron\">December 12, 2023<\/span> explicitly states the current composition of our Board of Directors (the &quot;Board&quot;), and Mr. <span class=\"xn-person\">Yi Zhang<\/span> is&nbsp;<b>not<\/b>&nbsp;the chairperson of our Board. Accordingly, Mr. Zhang does not have any authority to call a general meeting of shareholders of the Company.<\/li>\n<li><b>Extraordinary General Meeting<\/b>: Dr. <span class=\"xn-person\">Ajit Shetty<\/span>, currently the Interim Chairperson of the Board, has&nbsp;<b>not<\/b>&nbsp;called for an extraordinary general meeting of the Company to be held on <span class=\"xn-chron\">December 28, 2023<\/span>. Any communication suggesting otherwise is misleading and unauthorized. Shareholders are hereby advised to&nbsp;<b>disregard<\/b>&nbsp;the notice of the extraordinary general meeting purportedly published under our name and disseminated through PRNewswire. The meeting in question is&nbsp;<b>not<\/b>&nbsp;sanctioned by the Company and attendance is unnecessary.<\/li>\n<\/ol>\n<p>YS Biopharma encourages all stakeholders to seek accurate information from the Company&#8217;s official communications channels and refrain from acting on unauthorized statements.<\/p>\n<p><b>About YS Biopharma<\/b><\/p>\n<p>YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA&reg; immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">the United States<\/span>, <span class=\"xn-location\">Singapore<\/span> and <span class=\"xn-location\">the Philippines<\/span>, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit <a href=\"https:\/\/investor.ysbiopharm.com\/\" target=\"_blank\" rel=\"nofollow noopener\">investor.ysbiopharm.com<\/a>.<\/p>\n<p><b>Cautionary Statement Regarding Forward-Looking Statements<\/b><\/p>\n<p>This press release contains &#8221;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of YS Biopharma, the development progress of all product candidates, the progress and results of all clinical trials, YS Biopharma&#8217;s ability to source and retain talent, and the cash position of YS Biopharma following the closing of the Business Combination. Forward-looking statements may be identified by the use of words such as &quot;estimate,&quot; &quot;plan,&quot; &quot;project,&quot; &quot;forecast,&quot; &quot;intend,&quot; &quot;will,&quot; &quot;expect,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;seek,&quot; &quot;target&quot; or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of YS Biopharma&#8217;s management and are not predictions of actual performance.<\/p>\n<p>These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Although YS Biopharma believes that it has a reasonable basis for each forward-looking statement contained in this press release, YS Biopharma cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the final prospectus relating to the proposed Business Combination, and other documents filed by YS Biopharma from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.<\/p>\n<p>YS Biopharma cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the ability to recognize the anticipated benefits of the Business Combination, costs related to the transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts current plans and operations as a result of the consummation of the transaction, the outcome of any potential litigation, government or regulatory proceedings, the sales performance of the marketed vaccine product and the clinical trial development results of the product candidates of YS Biopharma, and other risks and uncertainties, including those included under the heading &quot;Risk Factors&quot; in the final prospectus filed with the SEC on <span class=\"xn-chron\">February 8, 2023<\/span>, as supplemented on <span class=\"xn-chron\">February 21, 2023<\/span>, and other filings with the SEC. There may be additional risks that YS Biopharma does not presently know or that YS Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of YS Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while YS Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of YS Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, YS Biopharma does not undertake any duty to update these forward-looking statements.<\/p>\n<p>Investor Relations Contacts<br \/><span class=\"xn-person\">Robin Yang<\/span><br \/>Partner,&nbsp;ICR, LLC<br \/>Tel: +1 (212) 537-4035<br \/>Email:&nbsp;<a href=\"mailto:YSBiopharma.IR@icrinc.com\" target=\"_blank\" rel=\"nofollow noopener\">YSBiopharma.IR@icrinc.com<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GAITHERSBURG, Md., Dec. 21, 2023 \/PRNewswire\/ &#8212; YS Biopharma Co., Ltd. (NASDAQ: YS) (&quot;YS Biopharma&quot; or the &quot;Company&quot;), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today issues an official response to the unauthorized press release disseminated under our name. [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-24046","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=24046\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting - My Blog\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., Dec. 21, 2023 \/PRNewswire\/ &#8212; YS Biopharma Co., Ltd. (NASDAQ: YS) (&quot;YS Biopharma&quot; or the &quot;Company&quot;), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today issues an official response to the unauthorized press release disseminated under our name. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=24046\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-20T21:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=24046#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=24046\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting\",\"datePublished\":\"2023-12-20T21:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=24046\"},\"wordCount\":1038,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=24046#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1911441\\\/YS_Biopharma_Logo.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=24046\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=24046\",\"name\":\"YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=24046#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=24046#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1911441\\\/YS_Biopharma_Logo.jpg?p=medium600\",\"datePublished\":\"2023-12-20T21:30:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=24046#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=24046\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=24046#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1911441\\\/YS_Biopharma_Logo.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/1911441\\\/YS_Biopharma_Logo.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=24046#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=24046","og_locale":"en_US","og_type":"article","og_title":"YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting - My Blog","og_description":"GAITHERSBURG, Md., Dec. 21, 2023 \/PRNewswire\/ &#8212; YS Biopharma Co., Ltd. (NASDAQ: YS) (&quot;YS Biopharma&quot; or the &quot;Company&quot;), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today issues an official response to the unauthorized press release disseminated under our name. [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=24046","og_site_name":"My Blog","article_published_time":"2023-12-20T21:30:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=24046#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=24046"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting","datePublished":"2023-12-20T21:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=24046"},"wordCount":1038,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=24046#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=24046","url":"https:\/\/transmediavictoria.net.au\/?p=24046","name":"YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=24046#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=24046#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600","datePublished":"2023-12-20T21:30:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=24046#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=24046"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=24046#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/1911441\/YS_Biopharma_Logo.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=24046#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/24046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24046"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/24046\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}